ConductScience.org, home

Paper32205232

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).

Runfeng L and 17 others. Pharmacol Res, 2020. Cited by 478 papers, by iCite.

Cite this record

ConductScience Library. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Papers, record 32205232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32205232

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).
PubMed
Journal
Pharmacol Res
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
478
iCite
Relative citation ratio, by iCite
26.9
iCite
Revised in PubMed
2021-11-22
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Runfeng LLi
2Yunlong HHou
3Jicheng HHuang
4Weiqi PPan
5Qinhai MMa
6Yongxia SShi
7Chufang LLi
8Jin ZZhao
9Zhenhua JJia
10Haiming JJiang
11Kui ZZheng
12Shuxiang HHuang
13Jun DDai
14Xiaobo LLi
15Xiaotao HHou
16Lin WWang
17Nanshan ZZhong
18Zifeng YYang

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory AgentsMajor topic
Antiviral AgentsMajor topic
BetacoronavirusMajor topic
Drugs, Chinese HerbalMajor topic
Animals
Cell Line
Chlorocebus aethiops
Microscopy, Electrochemical, Scanning
SARS-CoV-2

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04380870Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19Background

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in34802883Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761].https://conductscience.org/library/papers/34802883PubMed
Comment in33197600
Letter to the Editor in response to the articles 'Lianhuaqingwen exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2)' and 'Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway.'
https://conductscience.org/library/papers/33197600PubMed

Download CSV of comments and corrections

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132015507A pneumonia outbreak associated with a new coronavirus of probable bat origin.Nature2020https://conductscience.org/library/papers/32015507PubMed
216830000Clinical and laboratory findings of SARS in Singapore.Ann Acad Med Singap2006https://conductscience.org/library/papers/16830000PubMed
332020029Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell Res2020https://conductscience.org/library/papers/32020029PubMed
426868298Coronaviruses - drug discovery and therapeutic options.Nat Rev Drug Discov2016https://conductscience.org/library/papers/26868298PubMed
531996494Drug treatment options for the 2019-new coronavirus (2019-nCoV).Biosci Trends2020https://conductscience.org/library/papers/31996494PubMed
632145402Traditional Chinese medicine for COVID-19 treatment.Pharmacol Res2020https://conductscience.org/library/papers/32145402PubMed
731992388Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020.Euro Surveill2020https://conductscience.org/library/papers/31992388PubMed
831988464China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response.Nat Med2020https://conductscience.org/library/papers/31988464PubMed
923891402Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.Lancet Infect Dis2013https://conductscience.org/library/papers/23891402PubMed
1031774950A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.N Engl J Med2019https://conductscience.org/library/papers/31774950PubMed
1132031570Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.JAMA2020https://conductscience.org/library/papers/32031570PubMed
1231986264Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet2020https://conductscience.org/library/papers/31986264PubMed
1332004066Novel Wuhan (2019-nCoV) Coronavirus.Am J Respir Crit Care Med2020https://conductscience.org/library/papers/32004066PubMed
1431988490Outbreak of a novel coronavirus.Nat Rev Microbiol2020https://conductscience.org/library/papers/31988490PubMed
1531226023Human Coronavirus: Host-Pathogen Interaction.Annu Rev Microbiol2019https://conductscience.org/library/papers/31226023PubMed
1628085062Radix isatidis Polysaccharides Inhibit Influenza a Virus and Influenza A Virus-Induced Inflammation via Suppression of Host TLR3 Signaling In Vitro.Molecules2017https://conductscience.org/library/papers/28085062PubMed
1722040504Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.Chin Med J (Engl)2011https://conductscience.org/library/papers/22040504PubMed
1828235408The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function.BMC Complement Altern Med2017https://conductscience.org/library/papers/28235408PubMed

Download CSV of references

Cited by388

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 478 citations.

PMIDTitleJournalYearIn PapersSource
42947434Efficacy and safety of Lianhua Qingwen versus oseltamivir in children with influenza: a multicenter, randomized, double-blind, positive parallel-controlled study.Pharm Biol2026https://conductscience.org/library/papers/42947434PubMed
42568511Comparison of volatile organic compounds in different parts of Houttuynia cordata Thunb. via E-nose, GC-IMS, and multivariate statistical analysis.Front Nutr2026https://conductscience.org/library/papers/42568511PubMed
42549048The Redesign of the Molecular Scaffold of Viral Ion Channel Blockers.Comput Struct Biotechnol J2026https://conductscience.org/library/papers/42549048PubMed
42527947Forsythoside A alleviates experimental autoimmune encephalomyelitis by targeting Tnfaip2.Chin Med2026https://conductscience.org/library/papers/42527947PubMed
42504256Integrating the Wei-Qi-Ying-Blood Theory with Modern Pathophysiology: A Multitarget Translational Framework for Dengue Management.Int J Gen Med2026https://conductscience.org/library/papers/42504256PubMed
42475393Quercetin, a flavonoid, suppresses viral proliferation by interfering with the ubiquitin transfer from E1 to E2 enzymes.PLoS Pathog2026https://conductscience.org/library/papers/42475393PubMed
42453521Jing-Si Herbal Tea as a multitargeted complementary therapy: Evidence from preclinical and clinical studies.Tzu Chi Med J2026https://conductscience.org/library/papers/42453521PubMed
42370951Cloning and functional verification of genes LjHD8 and LjMIXTA1 related to trichome development in Lonicera japonica Thunb.Planta2026https://conductscience.org/library/papers/42370951PubMed
41971577Integrated network pharmacology, transcriptomics and experimental validation to explore mechanisms of Wenyang Jiedu Granule on IAV-induced pneumonia.Chin Herb Med2026https://conductscience.org/library/papers/41971577PubMed
41924162Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infect Drug Resist2026https://conductscience.org/library/papers/41924162PubMed
41909248Traditional Chinese medicine in influenza treatment: a bibliometric analysis integrating multiple databases.Front Microbiol2026https://conductscience.org/library/papers/41909248PubMed
41766236Effects of Traditional Chinese Medicine on Restoroing the immune balance of mild-to-moderate Patients with new coronavirus.Indian J Pharmacol2026https://conductscience.org/library/papers/41766236PubMed
41165505Molecular Roadmap of COVID-19: From Viral Entry to Therapeutic Targets.Chem Biodivers2026https://conductscience.org/library/papers/41165505PubMed
40872800Screening of Medicinal Herbs Identifies Cimicifuga foetida and Its Bioactive Component Caffeic Acid as SARS-CoV-2 Entry Inhibitors.Viruses2025https://conductscience.org/library/papers/40872800PubMed
40792265Mathematical modelling of the heterogeneity of disease progression and treatment outcomes in patients with COVID-19.Front Microbiol2025https://conductscience.org/library/papers/40792265PubMed
40746319Identification, functional analysis, and clinical applications of defective viral genomes.Front Microbiol2025https://conductscience.org/library/papers/40746319PubMed
40078906Role of innate immunity in SARS-CoV-2 infection.Biosaf Health2023https://conductscience.org/library/papers/40078906PubMed
40070503Pharmacological mechanism of action of Lianhua Qingwen in the treatment of COVID-19 and facial neuritis.World J Otorhinolaryngol Head Neck Surg2025https://conductscience.org/library/papers/40070503PubMed
39946361Effect of Chinese herbal medicine (CHM) as an adjunctive therapy in distinct stages of patients with COVID-19: A systematic review and meta-analysis.PLoS One2025https://conductscience.org/library/papers/39946361PubMed
39897928SARS-CoV-2 drug resistance and therapeutic approaches.Heliyon2025https://conductscience.org/library/papers/39897928PubMed

See all 388 cited byDownload CSV of cited by

Genes10

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32205232

GET https://conductscience.org/api/papers/v1/32205232/cited_by?page=2